| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 559.17 | 459.95 | 661.23 | 624.81 | 544.06 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 559.17 | 459.95 | 661.23 | 624.81 | 544.06 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 61.83 | 154.32 | 1,687.18 | 10.06 | 30.02 |
Total Income | 621 | 614.27 | 2,348.41 | 634.87 | 574.08 |
Total Expenditure | 579.23 | 557.91 | 675.09 | 549.62 | 534.53 |
PBIDT | 41.77 | 56.36 | 1,673.32 | 85.25 | 39.55 |
Interest | 3.58 | 4.44 | 180.84 | 185.34 | 173.98 |
PBDT | 38.19 | 51.92 | 1,492.48 | -100.09 | -134.43 |
Depreciation | 36.71 | 39.12 | 43.66 | 45.6 | 43.22 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0.69 | 2.56 | 400.73 | 2.32 | 39.96 |
Deferred Tax | 2.29 | 43.99 | -29.82 | -0.36 | -23.32 |
Reported Profit After Tax | -1.5 | -33.75 | 1,077.91 | -147.65 | -194.29 |
Minority Interest After NP | -0.33 | 0 | 0 | 0.04 | 0 |
Net Profit after Minority Interest | -1.17 | -33.75 | 1,077.91 | -147.69 | -194.29 |
Extra-ordinary Items | 33.05 | 56.11 | 1,275.48 | 0 | -11.81 |
Adjusted Profit After Extra-ordinary item | -34.22 | -89.86 | -197.57 | -147.69 | -182.48 |
EPS (Unit Curr.) | -0.19 | -5.43 | 175.98 | -24.11 | -31.72 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 7.47 | 12.25 | 253.06 | 13.64 | 7.26 |
PBDTM(%) | 6.82 | 11.28 | 225.71 | -16.01 | -24.7 |
PATM(%) | -0.26 | -7.33 | 163.01 | -23.63 | -35.71 |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
